Clinical trial
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NCT00000421 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00000421 |
|---|---|
| Title | Serologically Active, Clinically Stable Systemic Lupus Erythematosus |
| Official title | Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE) |
| Acronym | SACS-SLE |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | Prednisone, Placebo |
| Enrollment | 154 |
| Start date | Sep 1, 1997 |
| Primary completion | Aug 1, 2002 |
| Completion | Aug 1, 2003 |
| First posted | Nov 4, 1999 |
| Last update posted | Mar 4, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: